BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 12752436)

  • 1. Comparison of the solution structures of angiotensin I & II. Implication for structure-function relationship.
    Spyroulias GA; Nikolakopoulou P; Tzakos A; Gerothanassis IP; Magafa V; Manessi-Zoupa E; Cordopatis P
    Eur J Biochem; 2003 May; 270(10):2163-73. PubMed ID: 12752436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On the molecular basis of the recognition of angiotensin II (AII). NMR structure of AII in solution compared with the X-ray structure of AII bound to the mAb Fab131.
    Tzakos AG; Bonvin AM; Troganis A; Cordopatis P; Amzel ML; Gerothanassis IP; van Nuland NA
    Eur J Biochem; 2003 Mar; 270(5):849-60. PubMed ID: 12603318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin II vs its type I antagonists: conformational requirements for receptor binding assessed from NMR spectroscopic and receptor docking experiments.
    Wilkes BC; Masaro L; Schiller PW; Carpenter KA
    J Med Chem; 2002 Sep; 45(20):4410-8. PubMed ID: 12238921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conformational comparison of mu-selective endomorphin-2 with its C-terminal free acid in DMSO solution, by 1H NMR spectroscopy and molecular modeling calculation.
    In Y; Minoura K; Ohishi H; Minakata H; Kamigauchi M; Sugiura M; Ishida T
    J Pept Res; 2001 Nov; 58(5):399-412. PubMed ID: 11892849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1H-NMR studies of sarmesin and [des1]sarmesin conformation in dimethylsulfoxide by nuclear Overhauser effect (NOE) enhancement spectroscopy: folding of the N- and C-terminal domains.
    Matsoukas JM; Yamdagni R; Moore GJ
    Peptides; 1990; 11(2):367-74. PubMed ID: 2356160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Solution-state structure by NMR of zinc-substituted rubredoxin from the marine hyperthermophilic archaebacterium Pyrococcus furiosus.
    Blake PR; Park JB; Zhou ZH; Hare DR; Adams MW; Summers MF
    Protein Sci; 1992 Nov; 1(11):1508-21. PubMed ID: 1303769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conformational basis for the biological activity of TOAC-labeled angiotensin II and bradykinin: electron paramagnetic resonance, circular dichroism, and fluorescence studies.
    Schreier S; Barbosa SR; Casallanovo F; Vieira Rde F; Cilli EM; Paiva AC; Nakaie CR
    Biopolymers; 2004 Aug; 74(5):389-402. PubMed ID: 15222018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of the structure of lipid vesicle-bound angiotensin II and angiotensin I.
    Jalili PR; Dass C
    Anal Biochem; 2008 Mar; 374(2):346-57. PubMed ID: 18162166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural function of C-terminal amidation of endomorphin. Conformational comparison of mu-selective endomorphin-2 with its C-terminal free acid, studied by 1H-NMR spectroscopy, molecular calculation, and X-ray crystallography.
    In Y; Minoura K; Tomoo K; Sasaki Y; Lazarus LH; Okada Y; Ishida T
    FEBS J; 2005 Oct; 272(19):5079-97. PubMed ID: 16176278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solid-phase synthesis and conformational properties of angiotensin converting enzyme catalytic-site peptides: the basis for a structural study on the enzyme-substrate interaction.
    Galanis AS; Spyroulias GA; Pairas G; Manessi-Zoupa E; Cordopatis P
    Biopolymers; 2004; 76(6):512-26. PubMed ID: 15508121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An effort to understand the molecular basis of hypertension through the study of conformational analysis of losartan and sarmesin using a combination of nuclear magnetic resonance spectroscopy and theoretical calculations.
    Mavromoustakos T; Kolocouris A; Zervou M; Roumelioti P; Matsoukas J; Weisemann R
    J Med Chem; 1999 May; 42(10):1714-22. PubMed ID: 10346924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural similarities of micelle-bound peptide YY (PYY) and neuropeptide Y (NPY) are related to their affinity profiles at the Y receptors.
    Lerch M; Mayrhofer M; Zerbe O
    J Mol Biol; 2004 Jun; 339(5):1153-68. PubMed ID: 15178255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1H-NMR studies of [Sar1]angiotensin II conformation by nuclear Overhauser effect spectroscopy in the rotating frame (ROESY): clustering of the aromatic rings in dimethylsulfoxide.
    Matsoukas JM; Bigam G; Zhou N; Moore GJ
    Peptides; 1990; 11(2):359-66. PubMed ID: 2356159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring the structural consequences of Phe12-->D-Phe and Leu15-->Aib substitution in human/rat corticotropin releasing hormone. Implications for design of CRH antagonists.
    Spyroulias GA; Papazacharias S; Pairas G; Cordopatis P
    Eur J Biochem; 2002 Dec; 269(24):6009-19. PubMed ID: 12473096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conotoxin TVIIA, a novel peptide from the venom of Conus tulipa 2. Three-dimensional solution structure.
    Hill JM; Alewood PF; Craik DJ
    Eur J Biochem; 2000 Aug; 267(15):4649-57. PubMed ID: 10903497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure and reorientational dynamics of angiotensin I and II: a microscopic physical insight.
    Deleon KY; Patel AP; Kuczera K; Johnson CK; Jas GS
    J Biomol Struct Dyn; 2012; 29(6):671-90. PubMed ID: 22545998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proposals for the angiotensin II receptor-bound conformation by comparative computer modeling of AII and cyclic analogs.
    Joseph MP; Maigret B; Scheraga HA
    Int J Pept Protein Res; 1995 Dec; 46(6):514-26. PubMed ID: 8748712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-dimensional structure of an angiotensin II-Fab complex at 3 A: hormone recognition by an anti-idiotypic antibody.
    Garcia KC; Ronco PM; Verroust PJ; BrĂ¼nger AT; Amzel LM
    Science; 1992 Jul; 257(5069):502-7. PubMed ID: 1636085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Solution structure of the human pp60c-src SH2 domain complexed with a phosphorylated tyrosine pentapeptide.
    Xu RX; Word JM; Davis DG; Rink MJ; Willard DH; Gampe RT
    Biochemistry; 1995 Feb; 34(7):2107-21. PubMed ID: 7532003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural comparison between type I and type II antagonists: possible implications in the drug design of AT1 antagonists.
    Roumelioti P; Tselios T; Alexopoulos K; Mavromoustakos T; Kolocouris A; Moore GJ; Matsoukas JM
    Bioorg Med Chem Lett; 2000 Apr; 10(8):755-8. PubMed ID: 10782679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.